Supplementary file 1_Enhanced efficacy of tylvalosin tartrate enteric-coated granules agai

Supplementary file 1 contains data from a study evaluating a novel enteric-coated formulation of tylvalosin tartrate against Mycoplasma hyopneumoniae in pigs. The dataset includes in vitro minimum inhibitory concentration and biofilm inhibition results, as well as clinical trial outcomes from 60 pigs across six treatment groups. The data was authored by Jiajing Li and last updated on figshare in June 2026.

Use Cases

• Modeling dose-response relationships for antibiotic efficacy based on feed dosage levels and clinical outcomes.
• Comparing in vitro antibacterial activity against clinical trial results using MIC and biofilm inhibition data.
• Analyzing correlations between treatment dosage and metrics like lung lesion scores, cure rates, and weight gain.

Strengths

• Includes specific quantitative results, such as a MIC of 0.015625 μg/mL for the novel formulation.
• Clinical trial involved 60 pigs across six treatment groups with positive and negative controls.
• Reports concrete outcomes like a 70% cure rate and significant lung lesion score reduction (p < 0.01) for specific doses.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary file format is DOC, which may require conversion for structured data analysis.

Provenance

Source

Jiajing Li via figshare

Collection Method

Data collected from in vitro assays and a controlled clinical trial with 60 pigs.

Freshness

Last updated 2026-06-02 05:34:20; freshness should be verified.